Business, energy, technology, markets and global industry news from Business News Today

biologics

PharmaDeviceNews biologics
Pharma & Biotech

Is insitro’s TherML platform finally delivering on the AI-native promise for biologics and small molecules?

insitro has announced the acquisition of CombinAbleAI and launched its new TherML platform, a modality-agnostic, AI-powered system that integrates small molecules, oligonucleotides, and biologics into a unified therapeutic design stack. The move signals a strategic attempt to industrialize AI-native drug discovery across modalities while reducing late-stage attrition risks. What makes this acquisition different from typical

Read More
Pharma & Biotech

Eli Lilly taps Chai Discovery to accelerate biologics with AI-generated candidates

Eli Lilly partners with Chai Discovery to deploy AI for antibody drug design. Find out what this means for the future of biologics R&D.

Read More
Pharma & Biotech

Ustekinumab biosimilar approved in Japan: Can Samsung Bioepis expand its global autoimmune footprint?

Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia's biosimilar adoption. Find out what this means.

Read More
Pharma & Biotech

Elanco wins USDA approval for Befrena, expanding mAb options in canine dermatitis

USDA approves Elanco’s Befrena for canine allergic dermatitis. Find out what it means for vets, pet owners, and the mAb dermatology race.

Read More
Hypertrophic scar and fibrosis research
Pharma & Biotech

Can Mabwell’s anti-IL-11 antibody redefine scarring treatment through fibrosis reversal?

Mabwell doses first patient in Phase II trial of IL-11 antibody for pathological scarring. Find out what this means for fibrosis drug development.

Read More
Representative image: Chronic obstructive pulmonary disease lung inflammation and airway damage, illustrating the disease context targeted by emerging biologic therapies such as Mabwell’s anti‑ST2 antibody 9MW1911 in clinical development.
Pharma & Biotech

Mabwell’s anti-ST2 antibody 9MW1911 cleared for U.S. Phase IIa trial: Could this reshape COPD biologics?

Mabwell Biopharmaceuticals has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration to initiate a Phase IIa clinical study for its anti-ST2 monoclonal antibody, 9MW1911, in patients with moderate-to-severe chronic obstructive pulmonary disease. This regulatory milestone comes on the heels of a completed Phase IIa study in China, where Mabwell

Read More
Pharma & Biotech

Hansa Biopharma files BLA for imlifidase in kidney transplant desensitization: What this changes for U.S. patients

Hansa Biopharma files for FDA approval of imlifidase to enable kidney transplants in highly sensitized patients. Find out what changes next.

Read More
Representative image illustrating the convenience of once-daily oral TYK2 inhibitors like zasocitinib, which achieved PASI 90 and PASI 100 responses by week 16 in plaque psoriasis clinical trials.
Pharma & Biotech

Takeda’s zasocitinib hits key Phase 3 psoriasis goals, challenging oral and biologic rivals

Takeda Pharmaceutical Company Limited has reported positive topline results from two pivotal Phase 3 studies of its investigational drug zasocitinib (TAK-279), a once-daily oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The trials met all primary and secondary endpoints, with more than 50 percent of participants achieving near-complete skin clearance (PASI

Read More
Pharma & Biotech

Can Harbour BioMed’s deal with Bristol Myers Squibb redefine the future of multispecific antibodies?

Harbour BioMed has signed a global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multispecific antibodies. The deal could be worth over $1.1 billion across upfront payments, milestones, and royalties. It also signals growing interest in platforms capable of generating novel immunotherapies for complex diseases. The announcement is not

Read More
Medical Devices & Diagnostics

Inside Xtant Medical’s Strata launch: What sets it apart from legacy bone grafts

Xtant Medical Holdings, Inc. has launched its next-generation synthetic bone graft, nanOss Strata, in the United States. The graft, built from hydroxycarbonapatite (HCA), is designed to enhance bioactivity and integration in orthopedic and spinal surgeries. This launch follows the company’s strategic exit from non-core spinal implant assets, signaling a renewed focus on its biologics portfolio.

Read More